ArticleThe Journal of allergy and clinical immunology2023
Distinct trajectories distinguish antigen-specific T cells in peanut-allergic individuals undergoing oral immunotherapy.
Article in The Journal of allergy and clinical immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06554691 (Exploring the Immunological Basis in the Evolution of Tree Nut and Peanut Allergy During Treatment Care for Understanding Markers and Treatment Targets), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Exploring the Immunological Basis in the Evolution of Tree Nut and Peanut Allergy During Treatment Care for Understanding Markers and Treatment Targets
Who cites it
17 citing papers in PubMed.
- Understanding the Variability of Peanut-Oral Immunotherapy Responses by Multi-Omics Profiling of Immune Cells.Allergy · 2025Trial
- Gut microbial bile and amino acid metabolism associate with peanut oral immunotherapy failure.Nature communications · 2025Trial
- Trends in allergen-reactive CRTH2+ T cells and TARC associated with successful outcomes in a phase 2 cashew oral immunotherapy study.Frontiers in immunology · 2025Trial
- Coordinated changes in oral propionate, oral microbiota, and peripheral blood inflammatory processes during peanut oral immunotherapy.The Journal of allergy and clinical immunology · 2026Article
- Review
- Mixed Signals: T Cells as Architects of IgE Immunity.Immunological reviews · 2026Review
- T-cell mechanisms in atopic dermatitis.Allergologie select · 2026Review
- Allergenicity assessment of novel foods - lessons from immune endotyping of food-allergic patients.Frontiers in immunology · 2026Review
- Modulating the Allergen-Specific Immune Response to Achieve Remission of Food Allergy Through Oral Immunotherapy.Advances in experimental medicine and biology · 2026Review
- Biomarker-driven drug development for allergic diseases and asthma: An FDA public workshop.The Journal of allergy and clinical immunology · 2025Article
- Allergen-Encapsulating Nanoparticles Reprogram Pathogenic Allergen-Specific Th2 Cells to Suppress Food Allergy.Advanced healthcare materials · 2025Article
- Anti-IgE therapy versus allergen-specific immunotherapy for food allergy: weighing the pros and cons.Frontiers in immunology · 2025Review
- Role of human antigen-specific T cells in tolerance and IgE-mediated allergic reactions to food.Frontiers in immunology · 2025Review
- Immunomodulatory metabolites in IgE-mediated food allergy and oral immunotherapy outcomes based on metabolomic profiling.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2024Article
- Contribution of T cell subsets to different food allergic diseases.Immunological reviews · 2024Review
- The future of food allergy diagnosis.Frontiers in allergy · 2024Review
- Immune signatures predicting the clinical outcome of peanut oral immunotherapy: where we stand.Frontiers in allergy · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
Abstract
backgroundDespite similar clinical symptoms, peanut-allergic (PA) individuals may respond quite differently to the same therapeutic interventions.
objectiveThis study aimed to determine whether inherent qualities of cell response at baseline could influence response to peanut oral immunotherapy (PnOIT).
methodsWe first performed ex vivo T-cell profiling on peanut-reactive CD154
resultsOur data emphasize the heterogeneity of pTeff cell responses in PA participants with 2 mutually exclusive phenotypic entities (CCR6
conclusionDividing PA patients according to their individual peanut-specific T-cell profile may facilitate patient stratification in clinical settings by identifying which immunotypes might respond best to different therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.